Bull case
Why this leftover might be a real product question.
A disease-modifying CFLD path would not compete with PERT incumbents. Negative UDCA guidance leaves a documented pharmacologic hole if endpoints can be defined.
Pursue diligence · N6 · GI and CF liver disease
H5 · Disease-modifying CF liver disease
Opportunity Score: 60/100 · Evidence: Moderate
Worth a closer look — not a mandate to form a company This card inherits the parent leftover’s score. It is not a second ranking.
PERT is a solved product class. Advanced CFLD is small, severe, and untreated by a disease-modifying drug.
Not medical advice, not a recommendation to buy or sell any security, and not a claim that any opportunity should be funded.
HYPOTHESIS
A score or thesis. Always shown with evidence and a way to kill it.
PERT is a solved product class; advanced CFLD is small severe and untreated by a disease-modifying drug.
FACT
A published number with a source and a date. You can check it.
PERT use is 80.2%. Cirrhosis is 2.7% of the complications population (861 people). CFF recommends against routine UDCA to prevent advanced CFLD; UDCA was still prescribed in 10.1%. No approved disease-modifying CFLD therapy is in the MVP table.
ANALYSIS
A filter or count this project computed, such as the reviewed CF map.
N6 industry crowding is moderate (two units): ANG003 and NHS7108 are GI/lipase candidates, not liver disease-modifiers. The need scores 60/100 with evidence Moderate because the category mixes a solved enzyme class with a rare severe liver problem.
INTERPRETATION
What we think the fact and analysis mean. Not a score yet.
The interesting remaining gap is CFLD, not another pancreatic enzyme. 861 people with cirrhosis is a hard biotech n. Older-adult PERT decline is interpreted by CFF as milder surviving phenotypes, not solved pancreatic disease.
Bear case
Why it might already be solved, or never be a new company.
Portal-hypertension endpoints are slow and noisy. A lipase newco is incremental to an existing class. Liver-disease development in other rare diseases has long timelines that a CF-only vehicle may not support.
Counterarguments
Reasons a skeptical reader would push back.
- PERT whitespace is not the interesting claim; CFLD is, and CFLD may be too small.
- Industry GI crowding is about enzymes and nutrition, not cirrhosis.
- Transplant-censored tables may hide post-transplant liver disease and shrink the countable group further.
What would have to be true
Assumptions the bet needs. If these fail, the thesis fails.
Cirrhosis/portal-hypertension endpoints can be studied; the 861-person cirrhosis group is large enough for a development path; UDCA-negative guidance leaves a real gap.
Kill the idea if
A pre-committed rule. If this happens, drop the thesis rather than talking yourself into it.
Kill if the addressable advanced-CFLD population is too small for a trial or if a feasible endpoint cannot be defined.
What to check next
- Split N6 in any later scoring: PERT vs CFLD should not share one venture thesis.
- Confirm whether 861 is incident enough for a trial.
- Look for non-CF cholestatic or fibrotic analogs only as biology, not as a TAM overlay.
Verdict
Pursue diligence on CFLD endpoints and n, not on another PERT. Kill if the addressable advanced-liver group cannot support a trial.
This card inherits the parent need score. It is not a second ranking and not a funding recommendation.